Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
about
Rapamycin and mTOR kinase inhibitorsInflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatmentHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Neoplastic disease after liver transplantation: Focus on de novo neoplasmsThe potential for immunogenicity of autologous induced pluripotent stem cell-derived therapiesSuccinct guide to liver transplantation for medical studentsSystematic review of melanoma incidence and prognosis in solid organ transplant recipients.De novo papillary carcinoma in a renal allograft: the pros and cons of immunosuppressionRisk factors and outcomes for the development of malignancy in lung and heart-lung transplant recipients.Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS).Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF‑1α expression in vivo.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Vaccines and immunotherapeutics for the treatment of malignant diseaseMerkel cell carcinoma in immunosuppressed patients.Malignant transformation of respiratory papillomatosis in a solid-organ transplant patient: case report and literature review.Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Do inflammatory bowel disease therapies cause cancer?Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.CTLA4 polymorphisms and de novo malignancy risk after renal transplantation in Chinese recipients.Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Epithelial-myoepithelial parotid carcinoma after kidney transplantationIBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyEffectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progressionIncidence of malignancy after living kidney transplantation: a multicenter study from iran.Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in ratsTwelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipientsThe association between chronic renal failure and renal cell carcinoma may differ between black and white Americans.Better survival of renal cell carcinoma in patients with inflammatory bowel diseaseAre We Late in the Diagnosis of Malignities Occurring in Solid Organ Transplant Patients? 11 Years' Experience.The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder.Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.Cancer risk in patients receiving renal replacement therapy: A meta-analysis of cohort studies.Colon and rectal cancer after renal transplantation.Atrial Myxoma-Related to Chronic Immunosuppression: A case reportChromosomal aberrations in UVB-induced tumors of immunosuppressed mice.Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.A comparison of rat chronic progressive nephropathy with human renal disease-implications for human risk assessment.Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
P2860
Q24644623-24A39D0D-8814-47A0-B350-EFDE40D92B2EQ26745456-4DB09A5C-2192-4F7C-9088-19E24DE709FBQ26777409-D36C3118-56D7-4EE2-A8B2-F6C8CD42C9E8Q26798306-67D08D3F-488E-4BD1-A3DA-8660C3F59CBFQ26851666-24436782-641F-46F0-A51A-82D643FD02CAQ28075352-5314C3C1-750E-427B-B235-C606A45A1D78Q33618035-04C0F682-8ACD-4E1C-A99E-1E143E0ED05FQ33622320-9C106F00-5959-422F-BF56-FD654FAF5D12Q33836119-8CEE7056-E05F-49DD-8B2C-3C38F5A42BB3Q33871984-8D89D508-63F8-402A-972E-52933D2129BFQ33890996-A9AB7DC1-2488-4ED5-8FE9-51F9627835C5Q34078707-6E631C60-DEB6-4D86-A240-9E6C0749C833Q34170074-0A522CBD-8927-4B2C-96B2-92D61CB5C28FQ34309887-AE55FB90-022E-4826-8EDF-3936BC08585BQ34364567-3059F056-E147-4B3B-AEA2-EA5CF7352E6FQ34517466-A1AA3216-C204-43CD-A9E4-DFCF0464FE47Q34520662-327EBAAC-3FB2-463C-BF20-8779E9554D81Q34613890-59E26F03-1D52-4616-8ED6-ED1F7D613C74Q34655953-1275253D-3777-4182-8F8C-4E8DF5AA5F78Q35033897-D9F22E3B-AA47-44D5-9A1B-60F583A01B75Q35462692-2A1A98A7-2EA1-4B4D-BD87-58803856FE00Q35602278-668A8995-02B4-43DD-BDBF-8FE027BCF38DQ35670762-8E37C9E1-C685-411F-B7B0-D9301FAD4463Q35818080-FC5A13F3-07B0-443A-886E-8EF6DEF24163Q35973628-9F98C064-F981-4301-BF46-B7CFC47B7207Q36037651-332BC0AC-D52E-4DF0-869F-AF2262E23BA0Q36147346-685EB443-640C-400E-A047-9B042BEF4D72Q36400864-46B9DA63-3EF6-4313-AEE0-137EE7CCBCEDQ36491127-DF5D246E-F36C-4BEE-8705-FA94C51E9921Q36546056-B8EEFCB4-3A06-413E-BE49-98DE01D73861Q36688768-1415B36A-A309-48A7-9C2D-597E5A692736Q36805870-F05A4837-D4D1-4E43-A4B5-A848A890CD2FQ36985818-20319493-E46B-46F9-9D23-0EC66E1270BEQ37205246-AB139E30-1EC9-4389-AA9F-4F69266B6CA9Q37242687-332BA7DB-0C6A-4A4E-8285-F28B211CA2EAQ37258472-3D767BF7-7D25-48A2-B8C0-8705E5BD438EQ37337088-9A0CC9E7-A148-40CE-ABF2-0742B7D12546Q37456176-786E7C0A-8019-4B3D-87E0-2BD73E000E07Q37514291-228EA48F-5A5D-4DE7-8E6F-3C35E74DEE32Q37845384-1B5D8DA3-51B9-4783-B25A-11BC15B93068
P2860
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Immunosuppressive therapy and ...... cipients: a systematic review.
@en
type
label
Immunosuppressive therapy and ...... cipients: a systematic review.
@en
prefLabel
Immunosuppressive therapy and ...... cipients: a systematic review.
@en
P2860
P1433
P1476
Immunosuppressive therapy and ...... cipients: a systematic review.
@en
P2093
Alex Gutierrez-Dalmau
Josep M Campistol
P2860
P304
P356
10.2165/00003495-200767080-00006
P577
2007-01-01T00:00:00Z
P6179
1020986267